Kornimate/medical-research-clean huggingface dataset:
use of infrared spectroscopy in fast septic arthritis diagnosis

Conditions: Joint Effusion

Summary: to study the diagnostic performance of infrared spectroscopy on fresh synovial fluids in early septic arthritis diagnosis in patients with acute joint effusion

diagnosis of a joint effusion is frequently a medical emergency, especially when septic arthritis is suspected. septic arthritis diagnosis relies on microscopic and bacteriological analysis of synovial fluid obtained by arthrocentesis. direct microscopic examination can be made within 2 to 12 hours but it is negative in about 50 % of the cases. it is necessary to wait 72 hours to obtain the result of the culture and reasonably rule out the diagnosis of septic arthritis. a method of establishing an immediate etiological diagnosis could improve the care of patients with joint effusion that is a therapeutic emergency and justify a hospitalization and a parenteral antibiotic therapy.

Eligibility criteria:
inclusion criteria: * patients over 18 year old * patients with an acute arthritis defined by an evolution of less than 6 weeks * patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study * patients who received information about the protocol and have not expressed opposition to participate exclusion criteria: * patients opposing the study * protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
optimal analgesia for forefoot surgery

Conditions: Hallux Valgus; Conduction Block

Summary: a randomised trial comparing three analgesic strategies for patients undergoing forefoot surgery in a day-surgery setting.

forefoot surgery, including scarf-akin osteotomy surgery for bunion correction, is moderately painful orthopaedic surgery, commonly performed as a day-case procedure. admission for opiate analgesia constitutes a failure of management and financial disadvantage to the healthcare organisation. the investigators seek to establish which technique will result in the best analgesia out of ankle block, metatarsal block, or a combination of the two. as analgesia constitutes part of a return to function, an additional aim is to determine whether either of these approaches will result in an objective functional benefit to the participants. the trial seeks to recruit 23 patients into either of 3 groups: ankle + sham metatarsal; sham ankle + metatarsal; ankle + metatarsal.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * diagnosed with 1st metatarsal pathology requiring surgical correction * participant meets the criteria for operative management in our day-surgery unit exclusion criteria: * contraindication to general anaesthesia * diabetic neuropathy affecting lower limbs * peripheral neuropathy affecting lower limbs of any aetiology * revision surgery * lack of capacity to consent
effects of normobaric hypoxia during exercise in patients with pulmonary hypertension receiving sildenafil

Conditions: Hypertension, Pulmonary

Summary: to study the effect of acute normobaric hypoxia during exercise in patients with pulmonary hypertension with/without sildenafil


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form) * ph class i (pah) or iv (cteph) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmhg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmhg during baseline measures at the diagnostic right-heart catheterization exclusion criteria: * resting partial pressure of oxygen \<8 kilopascal at zürich altitude on ambient air * exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study * inability to follow the procedures of the study * patients who take nitrates * other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Keywords: hypoxia exercise blood markers
description of characteristics, such as age, previous and concurrent treatments, associated diseases, of patients with asthma treated with dupilumab (dupixent)

Conditions: Asthma

Summary: primary objective: the primary objective of the study is to characterize patients initiating dupixent for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including fractional exhaled nitric oxide \[feno\]), and concomitant treatments for asthma. secondary objectives: the secondary objectives of the study are: * to characterize real-world use patterns of dupixent for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching) * to assess the effectiveness of dupixent in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control) * to assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with dupixent * to collect data on healthcare resource utilization (hcru) * to collect safety data on study participants in the real-world setting.

each patient will be followed during 36 months.

Eligibility criteria:
- male or female, 12 years or older initiating treatment with dupixent for asthma according to the country-specific prescribing information willing and able to comply with the required clinic visits, study procedures and assessments. provided signed informed consent - most important exclusion criteria for potential participants patients who have a contraindication to dupixent according to the country-specific prescribing information treatment with dupixent within 6 months before the baseline visit. note: for patients who have been treated previously with dupixent a washout period of 6 months is required before visit 1. any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments patients currently participating in any interventional clinical trial which modifies patient care. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
effects of acute dietary sodium on cerebrovascular reactivity and blood pressure reactivity

Conditions: Blood Pressure; Cerebrovascular Reactivity

Summary: americans eat more salt than is recommended by the american heart association. this is important because consuming a high-salt diet is associated with an increased risk of cardiovascular events, like strokes and heart attacks. in fact, consuming one high-salt meal temporarily reduces blood vessel function and it is not uncommon for americans to consume high-salt meals. therefore, our laboratory is interested in determining if a single high-salt meal affects 1) brain blood vessel function at rest and 2) blood pressure responses during exercise.

excess dietary salt increases the risk of cardiovascular events like strokes and heart attacks, independent of resting blood pressure. recent data found that consuming one high-salt meal temporarily reduces endothelial function in the periphery. this decrease in endothelial function can lead to an exaggerated blood pressure response during exercise and may also attenuate cerebrovascular reactivity at rest. this is essential, because an exaggerated cardiovascular response to exercise and a decrease in brain blood vessel function at rest are risk factors for future cardiovascular events. the long-term goal is to determine how dietary salt adversely affects bp and cerebrovascular regulation. the objective of this proposal is to evaluate the impact of an acute dietary salt meal on bp response during exercise and cerebrovascular reactivity at rest. the investigators have 2 specific aims: 1) aim 1 will test the hypothesis that high dietary salt will reduce cerebrovascular reactivity, 2) aim 2 will test the hypothesis that high dietary salt will augment blood pressure reactivity during exercise. the findings of this project will shed light on how acute dietary salt affects the risk of cardiovascular events during a bout of exercise and long-term risk for cardiovascular disease and stroke.

Eligibility criteria:
inclusion criteria: * normal blood pressure * males, females, minorities exclusion criteria: * high blood pressure * body mass index (bmi \> 30 kg/m2) * smokers or nicotine users * those who are pregnant or planning to become pregnant * allergy to the tomato soup
evaluation of the neural therapy effect on long term postoperative discomforts in patients who undergo bilateral tubal ligation

Conditions: Pain, Postoperative; Neural Therapy of Huneke; Dysmenorrhea; Dyspareunia; Sterilization, Tubal

Summary: the aim of this study was to explore the effect of neural therapy on postoperative pain and discomfort such as abdominal swelling; and gynecologic symptoms such as dysmenorrhea, dyspareunia, amount of menstrual bleeding and vaginitis. it also aimed to find out any possible links between the clinical changes and pathophysiologic mechanisms. one hundred and thirteen patients were randomly divided into two groups (neural therapy and control). postoperative first day, neural therapy was applied to the t10 to s4 dermatomes and utero-vaginal ganglion in random with local anesthetic agent. all patients were recalled one year after the treatment. the visual analog scale (vas) were noted in both groups, also discomfort and gynecologic symptoms are recorded.


Eligibility criteria:
inclusion criteria: * patients who undergo bilateral tubal ligation exclusion criteria: * previous abdominal surgery * patients with diseases that could have neurologic complications (dm, sle ...)
clinical and pathologic studies of patients undergoing treatment with egfr inhibitors

Conditions: Anal, Colon, and Rectal Cancers; Head and Neck Cancer; Lung Cancer; Colon Cancer; Colonic Neoplasms; Colorectal Neoplasms; Colon/Rectal Cancer; Colon/Rectal Cancer Colon Cancer; Colon/Rectal Cancer Rectal Cancer; Colon/Rectal Cancer Anal Cancer; Head and Neck Cancers; Head and Neck Cancers Lip; Head and Neck Cancers Oral Cavity; Head and Neck Cancers Nasopharynx; Head and Neck Cancers Oropharynx; Head and Neck Cancers Hypopharynx; Head and Neck Cancers Larynx; Head and Neck Cancers Trachea; Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer Small Cell Lung Cancer (SCLC)

Summary: cetuximab, erlotinib, and panitumumab are all recently fda approved epidermal growth factor receptor (egfr) inhibitors that treat a wide variety of tumor types, such as colon, lung, and head and neck. blockade of the egfr results in inhibition of multiple downstream pathways, leading to slowed tumor growth. in addition, these inhibitors may enhance anti-tumor immune responses through uncharacterized mechanisms. while producing significant responses in many settings, egfr inhibitors also result in significant skin toxicity (rash) in a high percentage of patients. multiple studies have correlated the presence and severity of rash with clinical response. unfortunately, severe rash can often lead to dose delays, reductions, or even discontinuation of egfr inhibitors, thus limiting their efficacy. the mechanism of both the rash and its correlation with tumor response is poorly understood. skin biopsies display a robust leukocyte infiltrate, but a systematic analysis of the type of infiltrating leukocytes, activation state, or homing receptor expression has not been performed. chemokines and chemokine receptors control leukocyte trafficking to the skin and other tissue sites, and defined receptor profiles for skin-, gut-, and lung-homing leukocytes are well established. in this study, the investigators propose to evaluate the homing phenotype of leukocytes from peripheral blood and skin biopsies of patients receiving egfr inhibitors. the investigators will use rna microarrays to evaluate the expression of chemokines and other key genes regulated in skin during treatment. the investigators will utilize in vitro methods to investigate effects of egfr inhibitors on imprinting of t cell tissue-specific homing receptors. the investigators will examine correlations among the pathologic data, clinical findings, and tumor response. if validated, peripheral blood evaluation could potentially be used as a predictive indicator for patients receiving egfr inhibitors. this study may also identify novel targets for limiting skin toxicity while receiving egfr inhibitors, thus allowing maximal dosing and clinical response from these agents.


Eligibility criteria:
inclusion criteria: * patients are eligible if they have histologically proven adenocarcinoma, are planning to or currently undergoing treatment with an anti-egfr (epidermal growth factor receptor) therapy, and are 18 years of age or older. exclusion criteria: * none
effect of a combination of bundles on surgical-site infection after elective colorectal surgery

Conditions: Surgical Site Infection

Summary: a prospective randomized clinical trial will be performed. patients will be randomized in 2 groups. the experimental group will undergo the combined application of intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan-impregnated sutures and application of mupirocin ointment over the skin staples, in addition to the standard care measures. the control group undergo only the standard care measures. incisional surgical-site infection will be investigated.

a prospective randomized clinical trial will be performed. patients will be randomized in 2 groups. the experimental group will undergo the combined application of intraperitoneal irrigation with clindamycin (600mg) and gentamicin (240 mg) solution in 250 ml of normal saline, fascial closure with triclosan-impregnated polyglactin suture and application of mupirocin ointment over the skin staples, in addition to the standard care measures. the control group undergo only the standard care measures, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. in the control group, the fascial closure will be performed with a polyglactin suture (without triclosan impregnation). incisional surgical-site infection will be investigated.

Eligibility criteria:
inclusion criteria: * patients with colorectal cancer undergoing elective laparoscopic colorectal surgery with curative aims. exclusion criteria: * chronic renal failure * immunodeficiency status, including uncontrolled type 2 diabetes mellitus and patients under corticoid or immunosuppresive treatment
efficacy of vitamin d supplementation in multiple sclerosis (evidims)

Conditions: Multiple Sclerosis

Summary: examination of efficacy, safety and tolerability of vitamin d3 in the treatment of multiple sclerosis (ms).


Eligibility criteria:
inclusion criteria: * informed consent * age between 18 and 65 at randomization * relapsing-remitting ms according to the revised mcdonald-criteria (2005) * edss ≤ 6,0 * stable immunomodulatory treatment for at least 3 months * sufficient birth control (pearl-index \<1) and negative pregnancy test at screening/randomization exclusion criteria: * any other ms-course than rrms * treatment with high dose vitamin d within 6 months prior to randomization * patients who have received over the last three months prior to randomization, an immunomodulatory therapy with the exception of ifn-β1b (betaferon ®) * any condition that could interfere with mri or other study related investigation * intolerability to gd-dtpa * hypersensitivity to the drug colecalciferol * patients with sarcoidosis * presence or history of nephrolithiasis * pseudohypoparathyroidism * clinically relevant dysfunction of liver, bone narrow or kidney defined by the following laboratory values: * hb \<8.5 g / dl * wbc \<2.5 / nl * platelet count \<100/nl * creatinine clearance by cockcroft-gault formula: cl \<110ml/min (male) and cl \<95ml/min (female) * ast / alt\> 3.5 times higher than the upper reference value * bilirubin\> 2.0 mg / dl * hypercalcaemia\> 2.7 mmol / l * calcium / creatinine ratio in urine\> 1 * treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates * pregnancy or lactation period * participation in any clinical study within 3 months before or at any time during study * any medical, psychiatric or other condition that could interfere with the patient's ability to understand and give the informed consent, to comply with the protocol or to finish the study any ruling commitment or placement in an institution
naturopathic-pharmacological consultation in hematology

Conditions: Hematologic Diseases

Summary: the goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. the main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients. participants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.


Eligibility criteria:
inclusion criteria: 1. followed up for a hematological condition 2. ability to fill simple questionnaires in hebrew, russian or arabic 3. indication for consultation: 1. patient's request to expand knowledge about the use of dhs 2. patient using dhs 3. patient's desire to start using dhs 4. patient that is interested in hearing about the use of dhs for his/her health condition 5. medical or nursing team's recommendation to take dhs for medical treatment or to improve compliance with conventional treatment. exclusion criteria: none

Keywords: dietary supplements herbal supplements hematology safety consultation naturopath clinical pharmacist
routine evaluation of people living with cancer

Conditions: Cachexia; Cancer; Advanced Cancer; Quality of Life

Summary: people with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. as cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. this altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life. these areas are often studied in isolation, giving an incomplete picture. a detailed, holistic characterisation of this group of people does not exist. a robust characterisation of people with incurable cancer will allow identification and prioritisation of future research and has the potential to inform new therapeutics and provide justification for treatments. this study aims to collect information about symptoms and quality of life, weight loss and body composition, physical activity and the body's immune response to cancer. participants with incurable cancer will be recruited to the study from oncology and palliative medicine services in the uk. participants will answer questionnaires about quality of life and symptoms, have bloods taken for inflammatory marker and cytokine analysis and have their body composition measured by a variety of methods.


Eligibility criteria:
inclusion criteria: * patients with incurable cancer (metastatic cancer (clinical, histological, cytological or radiological evidence) or receiving anti-cancer therapy with palliative intent). * aged 18-years and over * written informed consent exclusion criteria: * any concomitant medical or psychiatric problems which, in the opinion of the investigator, would increase the risk of complication for the participant and/or investigator. * participants will not be able to take part in bio-impedance analysis if they have a pacemaker or implantable cardiac defibrillator.

Keywords: cancer advanced cancer incurable cancer body composition physical function symptoms cachexia quality of life systemic inflammatory response palliative medicine
evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

Conditions: Pain

Summary: evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.


Eligibility criteria:
inclusion criteria: * must have met the inclusion criteria for the preceding double-blind bid study in diabetic neuropathy or postherpetic neuralgia. * must have received study medication under double-blind conditions. exclusion criteria: * patients cannot participate if they experienced a serious adverse event during the previous double-blind bid study which was determined to be related to the study medication.
clinical efficacy trial of burdock root extract in patients with asymptomatic hyperuricaemia

Conditions: Hyperuricemia or Gout

Summary: multicentre, double-blind, randomized, placebo-controlled trial of the clinical efficacy of burdock root extract in patients with asymptomatic hyperuricemia, with the primary objective to assess the efficacy of the use of burdock root extract in patients with asymptomatic hyperuricaemia versus placebo


Eligibility criteria:
inclusion criteria: * hyperuricaemia confirmed by a laboratory, uric acid level from 360 to 540 μmol/l in women and from 420 to 540 μmol/l in men; * age from 35 to 65 years at the baseline; * patients examined by an experienced specialist not revealing any clinical evidences of gout or other somatic consequences of hyperuricaemia; * not taking any other nutritional additives; * women of reproductive age having negative pregnancy test at the baseline and at the end of the trial; * not taking any diuretics, or their administration based on a regimen usual for a patient, without changes; * not taking part in any other clinical trials; * consent and voluntarily signed informed consent form for participation in the clinical trial. exclusion criteria: * age \ 65 years; * fever (above 36.8 ос); * pregnancy and lactation; * patients with any somatic evidences of hyperuricaemia including gout taking antigout drugs during or within 6 months before the trial; * patients with mental disorders / taking antipsychotics or antidepressants; * patients not giving (informed) consent to participate in the trial; * patients causing doubts of the study doctor as to their motivation to comply with the trial; * presence of any concomitant decompensated diseases or acute conditions able to influence results of the trial; * alcohol abuse and drug addiction; * changes in taking diuretics within a month before and during the trial; * participation in any other clinical trial; * taking any nutritional additives.